article thumbnail

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

AuntMinnie

A 2018 study from the U.S. An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Americans today can expect to live long lives.

article thumbnail

Pharmacist sentenced in radiopharmaceutical criminal case

AuntMinnie

Evidence showed that Sheriff owned and was pharmacist in charge at Shertech, a pharmacy that provided nuclear and radiopharmaceutical drugs to medical facilities. Attorney's Office in the District of South Carolina.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA approves Lutathera for some pediatric patients

AuntMinnie

Food and Drug Administration (FDA) has approved Novartis' Lutathera (lutetium-177 [Lu-177]) DOTATATE radiopharmaceutical for treatment of pediatric patients who are 12 years old and older with somatostatin receptor (SSTR)-positive gastroentropancreatic neuroendocrine tumors (GEP-NETs).

article thumbnail

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Imaging Technology

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

article thumbnail

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,

article thumbnail

Will new CPT codes spark utilization of quantitative MRI?

AuntMinnie

In 2018, Alosco received nearly $800,000 from the National Institutes of Health's National Institute of Neurological Disorders and Stroke for the research. A widely used class of radiopharmaceuticals in the study of the neuroinflammatory response targets the translocator protein (TSPO), according to the researchers.

MRI 263
article thumbnail

Meet the Minnies 2024 finalists

AuntMinnie

In 2018 he received an endowed professorship from the university. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year.